Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 12475

1.

Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster.

Papadatou I, Lagousi T, Kattamis A, Spoulou V.

Ann Hematol. 2019 Mar;98(3):775-779. doi: 10.1007/s00277-019-03615-z. Epub 2019 Jan 25.

PMID:
30683996
2.

Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults.

Song JY, Cheong HJ, Noh JY, Choi MJ, Yoon JG, Lee SN, Kang SH, Jeong EJ, Jo YM, Kim WJ.

BMC Infect Dis. 2018 Dec 5;18(1):628. doi: 10.1186/s12879-018-3479-9.

3.

A randomized trial to assess retention rates using mobile phone reminders versus physical contact tracing in a potential HIV vaccine efficacy population of fishing communities around Lake Victoria, Uganda.

Kiwanuka N, Mpendo J, Asiimwe S, Ssempiira J, Nalutaaya A, Nambuusi B, Wambuzi M, Kabuubi B, Namuniina A, Oporia F, Nanvubya A, Ssetaala A.

BMC Infect Dis. 2018 Nov 21;18(1):591. doi: 10.1186/s12879-018-3475-0.

4.

Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.

Kumarasamy N, Poongulali S, Beulah FE, Akite EJ, Ayuk LN, Bollaerts A, Demoitié MA, Jongert E, Ofori-Anyinam O, Van Der Meeren O.

Medicine (Baltimore). 2018 Nov;97(45):e13120. doi: 10.1097/MD.0000000000013120.

5.

Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI): study protocol.

Hirsch A, Katz MA, Laufer Peretz A, Greenberg D, Wendlandt R, Shemer Avni Y, Newes-Adeyi G, Gofer I, Leventer-Roberts M, Davidovitch N, Rosenthal A, Gur-Arie R, Hertz T, Glatman-Freedman A, Monto AS, Azziz-Baumgartner E, Ferdinands JM, Martin ET, Malosh RE, Neyra Quijandría JM, Levine M, Campbell W, Balicer R, Thompson MG; SHIRI workgroup.

BMC Infect Dis. 2018 Nov 6;18(1):550. doi: 10.1186/s12879-018-3444-7.

6.

Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.

Ubillos I, Ayestaran A, Nhabomba AJ, Dosoo D, Vidal M, Jiménez A, Jairoce C, Sanz H, Aguilar R, Williams NA, Díez-Padrisa N, Mpina M, Sorgho H, Agnandji ST, Kariuki S, Mordmüller B, Daubenberger C, Asante KP, Owusu-Agyei S, Sacarlal J, Aide P, Aponte JJ, Dutta S, Gyan B, Campo JJ, Valim C, Moncunill G, Dobaño C.

BMC Med. 2018 Oct 31;16(1):197. doi: 10.1186/s12916-018-1186-4.

7.

Awareness and Vaccine Coverage of Hepatitis B among Cameroonian Medical Students.

Aroke D, Kadia BM, Anutebeh EN, Belanquale CA, Misori GM, Awa A, Mbanga CM, Ngek LT.

Biomed Res Int. 2018 Sep 25;2018:3673289. doi: 10.1155/2018/3673289. eCollection 2018.

8.

Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam.

Thang HV, Huong VM, Victor JC, Van CB, Nga NT, Be LV, Cuong NP, Tsvetnitsky V, Neuzil KM, Power M, Flores J.

Vaccine. 2018 Nov 12;36(46):6918-6925. doi: 10.1016/j.vaccine.2018.10.013. Epub 2018 Oct 15.

PMID:
30337172
9.

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.

Camisaschi C, Renne SL, Beretta V, Rini F, Spagnuolo RD, Tuccitto A, Podda MG, Parmiani G, Rivoltini L, Collini P, Castelli C, Luksch R.

BMC Cancer. 2018 Oct 16;18(1):983. doi: 10.1186/s12885-018-4910-8.

10.

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection.

Gerretsen HE, Capone S, Vitelli A, Reyes LS, Thompson A, Jones C, Green CA, Pollard AJ, Sande CJ.

Vaccine. 2018 Nov 12;36(46):6988-6994. doi: 10.1016/j.vaccine.2018.09.070. Epub 2018 Oct 11.

PMID:
30318168
11.

Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Vaccine. 2018 Nov 12;36(46):7017-7024. doi: 10.1016/j.vaccine.2018.09.057. Epub 2018 Oct 9.

PMID:
30314913
12.

Effects of natural infection by L. borgpetersenii serovar Hardjo type Hardjo-bovis and L. interrogans serovar Pomona, and leptospiral vaccination, on sheep growth.

Vallée E, Heuer C, Collins-Emerson JM, Benschop J, Ridler AL, Wilson PR.

Prev Vet Med. 2018 Nov 1;159:196-202. doi: 10.1016/j.prevetmed.2018.09.017. Epub 2018 Sep 17.

PMID:
30314782
13.

Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.

Zhang W, Lu X, Cui P, Piao C, Xiao M, Liu X, Wang Y, Wu X, Liu J, Yang L.

Cancer Immunol Immunother. 2019 Jan;68(1):121-130. doi: 10.1007/s00262-018-2257-2. Epub 2018 Oct 10.

PMID:
30306202
14.

The effect of exercise on local and systemic adverse reactions after vaccinations - Outcomes of two randomized controlled trials.

Lee VY, Booy R, Skinner SR, Fong J, Edwards KM.

Vaccine. 2018 Nov 12;36(46):6995-7002. doi: 10.1016/j.vaccine.2018.09.067. Epub 2018 Oct 6.

PMID:
30301642
15.

Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study.

Stanisic DI, Fink J, Mayer J, Coghill S, Gore L, Liu XQ, El-Deeb I, Rodriguez IB, Powell J, Willemsen NM, De SL, Ho MF, Hoffman SL, Gerrard J, Good MF.

BMC Med. 2018 Oct 8;16(1):184. doi: 10.1186/s12916-018-1173-9.

16.

Association of human leukocyte antigen alleles and supertypes with immunogenicity of oral rotavirus vaccine given to infants in China.

Liu Y, Guo T, Yu Q, Zhang H, Du J, Zhang Y, Xia S, Yang H, Li Q.

Medicine (Baltimore). 2018 Oct;97(40):e12706. doi: 10.1097/MD.0000000000012706.

17.

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié MA, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR.

N Engl J Med. 2018 Oct 25;379(17):1621-1634. doi: 10.1056/NEJMoa1803484. Epub 2018 Sep 25.

18.

Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.

Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, Wang J, Li C, Zhang Q, Gao Q, Hu Y.

Vaccine. 2018 Oct 29;36(45):6782-6789. doi: 10.1016/j.vaccine.2018.09.023. Epub 2018 Sep 21.

PMID:
30249424
19.

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.

Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, Dallas M, Hartzel J, Marchese RD, Coller BG, Stek JE, Abeygunawardana C, Winters MA, MacNair JE, Pujar NS, Musey L.

Vaccine. 2018 Oct 29;36(45):6883-6891. doi: 10.1016/j.vaccine.2018.02.113. Epub 2018 Sep 21.

PMID:
30244873
20.

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.

Kirstein J, Douglas W, Thakur M, Boaz M, Papa T, Skipetrova A, Plennevaux E.

BMC Infect Dis. 2018 Sep 21;18(1):475. doi: 10.1186/s12879-018-3389-x.

Supplemental Content

Loading ...
Support Center